GPT and metabolic dysfunction-associated steatotic liver disease: Furthermore, liver inflammation (Figure 3h) and plasma ALT/AST (Figure 3i) were not altered by either HFD feeding or GPA treatment in any group, indicating that GPA reduces hepatic lipid accumulation and body fat mass independent of its anti-inflammatory characteristics at the early stage of NAFLD.